ASX News
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Market Cap $8.512M
!
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| SRK | Ann: Quarterly Reports - 31 March 2025 | 04/08/25 | 10 | 8.0K | |||
|
|||||||
| SRK | Ann: Quarterly Reports - 30 June 2025 | 31/07/25 | 0 | 407 | |||
|
|||||||
| SRK | Ann: Notice of Change of Interests of Substantial Holder - GII | 28/07/25 | 0 | 257 | |||
|
|||||||
| SRK | Strike resources lacks basic visability | 06:27 | 2 | 779 | |||
|
|||||||
| SRK | Ann: Notice of Change of Interests of Substantial Holder - GII | 25/04/25 | 17 | 6.0K | |||
|
|||||||
| SRK | Ann: Half Year Report - 31 December 2024 | 14/03/25 | 0 | 560 | |||
|
|||||||
| SRK | Ann: Company Update | 11/03/25 | 3 | 4.5K | |||
|
|||||||
| SRK | Ann: Notification of cessation of securities - SRK | 17/02/25 | 0 | 462 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.512M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 3.0¢ | 2.9¢ | $1.634K | 56.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63828 | 2.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 4267 | 1 |
View Market Depth
| Last trade - 11.04am 22/08/2025 (20 minute delay) ? |
|
|||||
|
Last
2.9¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.9¢ | 2.9¢ | 2.9¢ | 43828 | ||
| Last updated 10.08am 22/08/2025 ? | |||||
| SRK (ASX) Chart |
